Related Experiment Videos
Buprenorphine: new pharmacological aspects.
1Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
International Journal of Clinical Practice. Supplement
|April 1, 2003
Summary
Buprenorphine, a potent opioid analgesic, acts as a partial mu-opioid receptor agonist. Its unique pharmacology, including a ceiling effect for respiratory depression, makes it valuable for managing opioid dependence with lower abuse potential.
Area of Science:
- Pharmacology
- Neuroscience
- Medicinal Chemistry
Background:
- Buprenorphine is an opioid analgesic derived from thebaine.
- Initially classified as a mixed agonist-antagonist, its action as a partial mu-opioid receptor agonist was established.
- Its lower abuse liability in humans led to its use in treating opioid dependence.
Purpose of the Study:
- To explore the unique pharmacological characteristics of buprenorphine.
- To understand its dose-response relationships and antinociceptive potency.
- To investigate the role of its metabolite, norbuprenorphine.
Main Methods:
- Animal models (chronic spinal dog, rodents) for assessing opioid receptor activity and antinociception.
- Human studies to evaluate abuse liability and respiratory effects.
- Pharmacological profiling including binding assays and dose-response curve analysis.
Main Results:
- Buprenorphine exhibits partial agonism at mu-opioid receptors with high affinity and slow dissociation.
- Demonstrated full efficacy in preclinical antinociceptive tests, with potency 25-40 times higher than morphine.
- Showed a ceiling effect for respiratory depression but not analgesia in humans.
Conclusions:
- Buprenorphine's unique pharmacological profile, including partial agonism and a ceiling effect, supports its therapeutic use in opioid dependence.
- Norbuprenorphine, a metabolite, contributes to buprenorphine's overall pharmacology and exhibits dose-dependent analgesic activity.